CÁNCER DE MAMA LUMINAL
TIPO
ENSAYO
FASE
ESTADO
ADYUVANCIA
EMBER 4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Fase 3
CERRADO
ADYUVANCIA
GO42784 (LIDERA):A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Fase 3
CERRADO
NEOADYUVANCIA
MK756: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Fase 3
CERRADO
METASTÁSICO
VIKTORIA:Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Fase 3
CERRADO
METASTÁSICO
SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
Fase 2
CERRADO
METASTÁSICO
DYNASTY-BREAST 02: A Study of DB-1303/BNT323 vs Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Fase 3
CERRADO
CÁNCER DE MAMA TRIPLE NEGATIVO
TIPO
ENSAYO
FASE
ESTADO
NEOADYUVANCIA
TROPION04:A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Fase 3
CERRADO
METASTÁSICO
TROPION02: A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Fase 2
CERRADO
METASTÁSICO
SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
Fase 2
CERRADO
CÁNCER DE HER 2 POSITIVO
TIPO
ENSAYO
FASE
ESTADO
NEOADYUVANCIA
PHERGAIN: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
Fase 2
CERRADO
METASTÁSICO
TUXEDO-3: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
Fase 2
CERRADO
METASTÁSICO
TUXEDO-4: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Fase 2
CERRADO
METASTÁSICO
ZN-A-1041: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Fase 1
CERRADO